tetano
Editor, Senior Moderator
Sci Rep
. 2023 Jun 7;13(1):9264.
doi: 10.1038/s41598-023-36429-1. Association of systemic adverse reaction patterns with long-term dynamics of humoral and cellular immunity after coronavirus disease 2019 third vaccination
Makoto Yoshida[SUP] 1 2 [/SUP], Yurie Kobashi[SUP] 2 3 [/SUP], Takeshi Kawamura[SUP] 4 5 [/SUP], Yuzo Shimazu[SUP] 2 [/SUP], Yoshitaka Nishikawa[SUP] 3 [/SUP], Fumiya Omata[SUP] 3 [/SUP], Hiroaki Saito[SUP] 2 [/SUP], Chika Yamamoto[SUP] 2 [/SUP], Tianchen Zhao[SUP] 2 [/SUP], Morihiro Takita[SUP] 2 [/SUP], Naomi Ito[SUP] 2 [/SUP], Kenji Tatsuno[SUP] 6 [/SUP], Yudai Kaneko[SUP] 5 7 [/SUP], Aya Nakayama[SUP] 4 [/SUP], Tatsuhiko Kodama[SUP] 5 [/SUP], Masatoshi Wakui[SUP] 8 [/SUP], Kenzo Takahashi[SUP] 9 10 [/SUP], Masaharu Tsubokura[SUP] 11 12 13 [/SUP]
Affiliations
The objective of this study was to clarify the impact of adverse reactions on immune dynamics. We investigated the pattern of systemic adverse reactions after the second and third coronavirus disease 2019 (COVID-19) vaccinations and their relationship with immunoglobulin G against severe acute respiratory syndrome coronavirus 2 spike 1 protein titers, neutralizing antibody levels, peak cellular responses, and the rate of decrease after the third vaccination in a large-scale community-based cohort in Japan. Participants who received a third vaccination with BNT162b2 (Pfizer/BioNTech) or mRNA-1273 (Moderna), had two blood samples, had not had COVID-19, and had information on adverse reactions after the second and third vaccinations (n = 2198) were enrolled. We collected data on sex, age, adverse reactions, comorbidities, and daily medicine using a questionnaire survey. Participants with many systemic adverse reactions after the second and third vaccinations had significantly higher humoral and cellular immunity in the peak phase. Participants with multiple systemic adverse reactions after the third vaccination had small changes in the geometric values of humoral immunity and had the largest geometric mean of cellar immunity in the decay phase. Systemic adverse reactions after the third vaccination helped achieve high peak values and maintain humoral and cellular immunity. This information may help promote uptake of a third vaccination, even among those who hesitate due to adverse reactions.
. 2023 Jun 7;13(1):9264.
doi: 10.1038/s41598-023-36429-1. Association of systemic adverse reaction patterns with long-term dynamics of humoral and cellular immunity after coronavirus disease 2019 third vaccination
Makoto Yoshida[SUP] 1 2 [/SUP], Yurie Kobashi[SUP] 2 3 [/SUP], Takeshi Kawamura[SUP] 4 5 [/SUP], Yuzo Shimazu[SUP] 2 [/SUP], Yoshitaka Nishikawa[SUP] 3 [/SUP], Fumiya Omata[SUP] 3 [/SUP], Hiroaki Saito[SUP] 2 [/SUP], Chika Yamamoto[SUP] 2 [/SUP], Tianchen Zhao[SUP] 2 [/SUP], Morihiro Takita[SUP] 2 [/SUP], Naomi Ito[SUP] 2 [/SUP], Kenji Tatsuno[SUP] 6 [/SUP], Yudai Kaneko[SUP] 5 7 [/SUP], Aya Nakayama[SUP] 4 [/SUP], Tatsuhiko Kodama[SUP] 5 [/SUP], Masatoshi Wakui[SUP] 8 [/SUP], Kenzo Takahashi[SUP] 9 10 [/SUP], Masaharu Tsubokura[SUP] 11 12 13 [/SUP]
Affiliations
- PMID: 37286720
- DOI: 10.1038/s41598-023-36429-1
The objective of this study was to clarify the impact of adverse reactions on immune dynamics. We investigated the pattern of systemic adverse reactions after the second and third coronavirus disease 2019 (COVID-19) vaccinations and their relationship with immunoglobulin G against severe acute respiratory syndrome coronavirus 2 spike 1 protein titers, neutralizing antibody levels, peak cellular responses, and the rate of decrease after the third vaccination in a large-scale community-based cohort in Japan. Participants who received a third vaccination with BNT162b2 (Pfizer/BioNTech) or mRNA-1273 (Moderna), had two blood samples, had not had COVID-19, and had information on adverse reactions after the second and third vaccinations (n = 2198) were enrolled. We collected data on sex, age, adverse reactions, comorbidities, and daily medicine using a questionnaire survey. Participants with many systemic adverse reactions after the second and third vaccinations had significantly higher humoral and cellular immunity in the peak phase. Participants with multiple systemic adverse reactions after the third vaccination had small changes in the geometric values of humoral immunity and had the largest geometric mean of cellar immunity in the decay phase. Systemic adverse reactions after the third vaccination helped achieve high peak values and maintain humoral and cellular immunity. This information may help promote uptake of a third vaccination, even among those who hesitate due to adverse reactions.